EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020)

Jennifer C Chan iD, Jonathan Dear iD, Carrie Palm iD, Krystle Reagan iD

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16728 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2023. Written by Jennifer C Chan and 3 co-authors. Institution: William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, California, USA. Major MEDLINE topics: Mycoses, Acute Kidney Injury, Dog Diseases. Cited 3 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Amphotericin-B (AmB) is an essential medication for the treatment of life-threatening systemic mycoses but the incidence and risk factors for acute kidney injury (AKI) after its administration are not known in dogs.

Objective

Determine the incidence of and risk factors for AKI in dogs receiving AmB. Animals Fifty-one client owned dogs receiving AmB for the treatment of systemic mycoses.

Methods

Retrospective study. Signalment, potential risk factors, AKI development (creatinine ≥0.3 mg/dL from baseline), drug formulation (deoxycholate [AmB-D] or lipid complex [ABLC]), dose, and treatment duration were recorded. The probability of an AKI diagnosis was evaluated using a log-rank test. The incidence of AKI and odds ratios were calculated for potential risk factors.

Results

Incidence of AKI was 5/12 (42%) for dogs receiving AmB-D and 14/39 (36%) for dogs receiving ABLC. Of the 19 dogs that developed AKI, 16 (84%) continued treatment after a pause in the planned dosing protocol. Fifty percent of dogs received a cumulative dose of 6.9 mg/kg for AmB-D and 22.5 mg/kg for ABLC (P < .01) at time of AKI diagnosis. ICU hospitalization (odds ratio [OR] 0.21, 95% confidence interval [CI]: 0.58-0.87) and inpatient status (OR 0.25, 95% CI: 0.07-0.86) were associated with decreased odds of AKI. Conclusions and Clinical Importance Incidence of AKI with AmB is common but does not always preclude continued treatment. The incidence of AKI is similar between AmB-D and ABLC, but dogs receiving ABLC tolerated a higher cumulative total dose before AKI diagnosis.

Subjects

MeSH terms (MEDLINE)

MycosesAcute Kidney InjuryDog DiseasesDogsAnimalsAmphotericin BAntifungal AgentsRetrospective StudiesIncidence

Author keywords

aspergillosisfungalfungicidalnephrotoxicity

Substances

Amphotericin BAntifungal Agents

Authors and institutions

  • William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, California, USA.
  • Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, California, USA.

ORCID profiles: Jennifer C Chan, Jonathan Dear, Carrie Palm, Krystle Reagan

Cite

APA

Chan, J. C., Dear, J., Palm, C., & Reagan, K. (2023). Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020). Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16728

Vancouver

Chan JC, Dear J, Palm C, Reagan K. Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020). Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16728

BibTeX
@article{Chan2023,
  author = {Chan, Jennifer C and Dear, Jonathan and Palm, Carrie and Reagan, Krystle},
  title = {Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020)},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16728}
}
Start for free →